Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism myf6 expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 2
from Ganassi et al., 2018
|
myotome skeletal muscle cell myog expression absent, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 1
from Ganassi et al., 2018
|
myotome skeletal muscle cell myog expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 1
from Ganassi et al., 2018
|
whole organism myog expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 1
from Ganassi et al., 2018
|
myotome fast muscle cell disorganized, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 2
from Ganassi et al., 2018
|
whole organism mymk expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 5 ,
Fig. 6
from Ganassi et al., 2018
|
myotome skeletal muscle tissue development decreased process quality, abnormal
|
myogkg125/kg125 (TL)
|
control
|
Fig. 6
from Ganassi et al., 2018
|
whole organism mymx expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 5
from Ganassi et al., 2018
|
somite skeletal muscle cell mymk expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
chemical treatment by environment: Cyclopamine
|
Fig. 6
from Ganassi et al., 2018
|
whole organism mymk expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
chemical treatment by environment: Cyclopamine
|
Fig. 6
from Ganassi et al., 2018
|
whole organism jam3b expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 5
from Ganassi et al., 2018
|
myotome skeletal muscle tissue development decreased process quality, exacerbated
|
myogkg125/kg125 (TL)
|
chemical treatment by environment: Cyclopamine
|
Fig. 6
from Ganassi et al., 2018
|
whole organism decreased weight, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 7
from Ganassi et al., 2018
|
somite skeletal muscle cell mymk expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 6
from Ganassi et al., 2018
|
skeletal muscle cell nucleus myog expression absent, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 1
from Ganassi et al., 2018
|
whole organism myf5 expression decreased amount, abnormal
|
myogkg125/kg125 (TL)
|
standard conditions
|
Fig. 2
from Ganassi et al., 2018
|
myotome decreased height, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 3
from Ganassi et al., 2018
|
myotome skeletal muscle cell myog expression decreased amount, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 1
from Ganassi et al., 2018
|
myotome fast muscle cell decreased area, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 7
from Ganassi et al., 2018
|
fast muscle cell has fewer parts of type fast muscle cell nucleus, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 7
from Ganassi et al., 2018
|
whole organism decreased weight, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 7
from Ganassi et al., 2018
|
somite skeletal muscle cell mymk expression decreased amount, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 5
from Ganassi et al., 2018
|
somite skeletal muscle cell jam3b expression decreased amount, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 5
from Ganassi et al., 2018
|
myotome has extra parts of type fast muscle cell, abnormal
|
myogkg128/kg128 (TL)
|
standard conditions
|
Fig. 7
from Ganassi et al., 2018
|
fast muscle cell myoblast fusion decreased occurrence, abnormal
|
myogkg125/kg125; vu119Tg
|
control
|
Fig. 6
from Ganassi et al., 2018
|
fast muscle cell myoblast fusion decreased occurrence, exacerbated
|
myogkg125/kg125; vu119Tg
|
chemical treatment by environment: Cyclopamine
|
Fig. 6
from Ganassi et al., 2018
|
fast muscle cell has fewer parts of type fast muscle cell nucleus, abnormal
|
myogkg128/kg128; vu119Tg
|
standard conditions
|
Fig. 4
from Ganassi et al., 2018
|
myotome has extra parts of type fast muscle cell, abnormal
|
myogkg128/kg128; vu119Tg
|
standard conditions
|
Fig. 3
from Ganassi et al., 2018
|
fast muscle cell myoblast fusion decreased occurrence, abnormal
|
myogkg128/kg128; vu119Tg
|
standard conditions
|
Fig. 4
from Ganassi et al., 2018
|
myotome fast muscle cell decreased volume, abnormal
|
myogkg128/kg128; vu119Tg
|
standard conditions
|
Fig. 3
from Ganassi et al., 2018
|
fast muscle cell nucleus centered, abnormal
|
myogkg128/kg128; vu119Tg
|
standard conditions
|
Fig. 4
from Ganassi et al., 2018
|
myotome decreased volume, abnormal
|
myogkg128/kg128; vu119Tg
|
standard conditions
|
Fig. 3
from Ganassi et al., 2018
|